scholarly article | Q13442814 |
P50 | author | Alberto Bardelli | Q28321691 |
Andrea Sartore-Bianchi | Q28321693 | ||
Salvatore Siena | Q28321703 | ||
Vincenzo Sforza | Q56953948 | ||
P2093 | author name string | Fortunato Ciardiello | |
Anna Maria Rachiglio | |||
Nicola Normanno | |||
Teresa Troiani | |||
Erika Martinelli | |||
Davide Ciardiello | |||
Giulia Martini | |||
Silvia Marsoni | |||
Pietro Paolo Vitiello | |||
Claudia Cardone | |||
P2860 | cites work | Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 |
Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
HER2 activating mutations are targets for colorectal cancer treatment | Q27853193 | ||
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer | Q28076490 | ||
EGFR antagonists in cancer treatment | Q29616740 | ||
ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Q38384113 | ||
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas | Q39013804 | ||
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial | Q45217739 | ||
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. | Q52861120 | ||
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. | Q54279287 | ||
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. | Q54343844 | ||
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. | Q55080669 | ||
P433 | issue | 1 | |
P921 | main subject | colorectal cancer | Q188874 |
metastatic colon cancer | Q108566365 | ||
P304 | page(s) | e000299 | |
P577 | publication date | 2018-01-10 | |
P1433 | published in | ESMO Open | Q53951848 |
P1476 | title | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case | |
P478 | volume | 3 |
Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
Q92522562 | Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models |
Q57183898 | Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status |
Q64890286 | How I treat cancer special issue. |
Q90017841 | Implementation of genomic medicine for gastrointestinal tumors |
Q98386286 | Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer |
Q92280751 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study |
Q90513170 | Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer |
Q90711036 | Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study |
Q92747984 | Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer |
Q54962247 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. |
Search more.